Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus docetaxel versus docetaxel alone as second-line or later therapy for advanced non-squamous non-small cell lung cancer
ChiCTR1800019808Phase 2Recruiting
- Sponsor
- Affiliated Hospital of North Sichuan Medical College
- Start
- Nov 2016
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of Rivoceranib and docetaxel in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Affiliated Hospital of North Sichuan Medical College. Primary endpoint: progression-free survival. Started Nov 2016; status: recruiting.
02
Drugs
Rivoceranibdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR1800019808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019808.